Clinic Roundup

• Cytomedix Inc., of Gaithersburg, Md., said data from a randomized Phase I trial of ALD-201 in ischemic heart failure were published in the online edition of the American Heart Journal. The study enrolled 20 heart failure patients with no treatment options, evaluating safety as the primary endpoint.